Published in Hepatitis Weekly, July 24th, 2000
In discussing the theory behind their in vivo study, S. Elmir and co-investigators at the Institute Gustave Roussy in Villejuif, France, said, "The lymphocyte activation gene-3 (LAG-3) product is a MHC (major histocompatibility complex) class II ligand that has been used in vivo to stimulate MHC II+ APCs (antigen-presenting cells) to increase tumor-specific immune responses."
To look at the effect of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2000-07-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.